New TB vaccine could produce large health, economic benefits in LMICs
Introducing an effective new tuberculosis vaccine in low- and middle-income countries could lead to billions of dollars in potential health and economic benefits, according to a modeling study led by Harvard Chan School.
Report makes the case for new TB vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment, according to a new report.
Researchers launch COVID-19 model to better understand county-level trends
A new statistical model developed by researchers from Harvard Chan School and Yale School of Public Health provides a tool for analyzing COVID-19 outcomes and making near real-time projections at a local level about disease spread.
TB unlikely to be eliminated in U.S. anytime soon
But a greater focus on testing and treatment, particularly among immigrants, could speed the disease’s decline, study finds May 21, 2018 – Although tuberculosis (TB) is on the wane in the U.S., there’s little chance that the nation…
Helping nations assess and manage immunization costs
July 21, 2016 -- As new vaccines are introduced—some of them quite costly—accurate information on the cost and financing of national immunization programs can be lacking. Research and a new website developed at Harvard T.H. Chan School of…
